Pierre Sargis Sayad - 28 Mar 2025 Form 4 Insider Report for FENNEC PHARMACEUTICALS INC. (FENC)

Reporting relationship: Chief Medical Officer
Issuer ticker: FENC
Reported as of: 28 Mar 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Apr 2025, 19:15:41 UTC
Prior SEC filing: 13 Nov 2024
Next SEC filing: 02 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Pierre Sayad

Key filing fact

Pierre Sargis Sayad filed Form 4 for FENNEC PHARMACEUTICALS INC. (FENC) on 03 Apr 2025.

Key facts

This page summarizes Pierre Sargis Sayad's Form 4 filing for FENNEC PHARMACEUTICALS INC. (FENC).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Apr 2025, 19:15.

Change

Previous filing in this sequence was filed on 13 Nov 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

FENC transaction Derivative

Restricted Share Unit

Award

Transaction value: $0
Shares: +10,000
Change %: +6.7%
Price: $0.000000
Shares after: 160,000
Date: 28 Mar 2025
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 10,000
Exercise price: $0.000000
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On March 28, 2025, Pierre Sayad was awarded restricted share units to acquire 10,000 shares of the issuer's common shares pursuant to the issuer's 2020 Equity Incentive Plan.

Footnote F2

One-third of the shares subject to this award shall be released from restriction as of March 28, 2026 (the "Vesting Commencement Date"). One twenty-fourth of the shares subject to this award may be released from restriction as of the last day of each month following the Vesting Commencement Date. As of February 29, 2028 and thereafter, 100% of the total number of shares subject to this award shall be released from restriction.